je.st
news
Tag: patients
Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy
2015-12-02 02:15:49| drugdiscoveryonline Home Page
Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, recently announced a collaboration to explore the potential utility of daily physiological activity monitoring in boys affected by Duchenne muscular dystrophy (DMD) with ActiGraph, a leading provider of objective physical activity and sleep/wake measurement solutions for the global scientific community
Tags: with
daily
activity
trial
Mipsagargin Demonstrates Clinical Benefit In Subset Of Glioblastoma Patients
2015-12-02 02:02:20| drugdiscoveryonline Home Page
GenSpera Inc., a biotech company developing a novel prodrug therapeutic for the treatment of cancer, recently announced results from the Phase II study investigating the use of mipsagargin (G-202) for the treatment of glioblastoma multiforme
Tags: benefit
patients
clinical
demonstrates
Real life Dallas Buyers Club operation helps hepatitis C patients with free drugs
2015-11-30 13:55:15| Biotech - Topix.net
A Dallas Buyers Club- style operation that helps hepatitis C patients get lifesaving drugs at knockdown prices plans to go a step further for World Aids Day on Tuesday - free drugs for those who can least afford them. Nearly a quarter of a million Australians carry hepatitis C, a "viral time bomb" that kills half a million people worldwide each year, according to the World Health Organisation.
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting
2015-11-15 01:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Poor air quality increases patients' risk of heart attack
2015-11-08 22:02:00| Climate Ark Climate Change & Global Warming Newsfeed
ScienceDaily: People with heart disease face an increased risk of a serious heart attack during poor air quality days, according to a major new study presented today at the American Heart Association Scientific Session in Orlando. The study of more than 16,000 patients by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City examined patients who had suffered three types of heart attacks -- STEMI, non-STEMI, and unstable angina -- to identify which type of heart attack was more likely...
Sites : [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »